# Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

> **NCT04624906** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 63 (actual)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Bendamustine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04624906
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-02
- **Primary completion:** 2025-12-31
- **Final completion:** 2030-03
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624906, "Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04624906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*